Status:
UNKNOWN
Biomarker Guided Treatment in DLBCL
Lead Sponsor:
Ruijin Hospital
Conditions:
Diffuse Large B Cell Lymphoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma
Eligibility Criteria
Inclusion
- Pathologically confirmed diffuse large B-cell lymphoma, CD20 positive
- ECOG 0,1,2
- Life expectancy\>6 months
- Informed consented
- IPI\>1
Exclusion
- Chemotherapy before
- Stem cell transplantation before
- History of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
- Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease
- Primary CNS lymphoma
- LVEF≤50%
- Lab at enrollment (Unless caused by lymphoma) Neutrophile\<1.5\*10\^9/L Platelet\<75\*10\^9/L ALT or AST \>2\*ULN,AKP or bilirubin \>1.5\*ULN Creatinine\>1.5\*ULN Other uncontrollable medical condition that may that may interfere the participation of the study Not able to comply to the protocol for mental or other unknown reasons Pregnant or lactation HIV infection If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA,DNA positive patients cannot be enrolled.
Key Trial Info
Start Date :
July 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT04025593
Start Date
July 17 2019
End Date
June 1 2023
Last Update
November 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin hospital
Shanghai, Shanghai Municipality, China, 200025